×
About 26,970 results

ALLMedicine™ Acute Myeloid Leukemia Center

Research & Reviews  9,281 results

Dose intensity for induction in acute myeloid leukemia: what, when, and for whom?
https://doi.org/10.3324/haematol.2020.269134
Haematologica McCurdy SR, Luger SM

Jul 30th, 2021 - Intensive chemotherapy has been the backbone of the treatment of acute myeloid leukemia (AML) for decades. However, an increase in novel targeted agents, which has been brought about in part by a deeper understanding of the genetic makeup of AML, ...

Preclinical Drug Metabolism, Pharmacokinetic, and Pharmacodynamic Profiles of Ivosideni...
https://doi.org/10.1124/dmd.120.000234
Drug Metabolism and Disposition: the Biological Fate of C... Chen Y, Nagaraja NV et. al.

Jul 30th, 2021 - Point mutations in isocitrate dehydrogenase 1 (IDH1) result in conversion of α-ketoglutarate to the oncometabolite, D-2-hydroxyglutarate (2-HG). Ivosidenib is a once daily (q.d.), orally available, potent, mutant IDH1 (mIDH1) inhibitor approved fo...

A 2:1 randomized, open-label, phase II study of selinexor vs. physician's choice in old...
https://doi.org/10.1080/10428194.2021.1950706
Leukemia & Lymphoma; Sweet K, Bhatnagar B et. al.

Jul 30th, 2021 - Selinexor, a selective inhibitor of nuclear export, has demonstrated promising activity in patients with acute myeloid leukemia (AML). This randomized, phase II study evaluated selinexor 60 mg twice weekly (n = 118) vs. physician's choice (PC) tre...

see more →

Guidelines  10 results

Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myel...
https://doi.org/10.1016/j.bbmt.2020.09.020
Biology of Blood and Marrow Transplantation : Journal of ... Dholaria B, Savani BN et. al.

Sep 24th, 2020 - The role of hematopoietic cell transplantation (HCT) in the management of newly diagnosed adult acute myeloid leukemia (AML) is reviewed and critically evaluated in this evidence-based review. An AML expert panel, consisting of both transplant and...

NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018.
https://doi.org/10.6004/jnccn.2017.0157
Journal of the National Comprehensive Cancer Network : JN... Mesa RA, Jamieson C et. al.

Oct 7th, 2017 - Myeloproliferative neoplasms (MPNs) are a group of heterogeneous disorders of the hematopoietic system that include myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). PV and ET are characterized by significant thromboh...

Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2017.0116
Journal of the National Comprehensive Cancer Network : JN... O'Donnell MR, Tallman MS et. al.

Jul 9th, 2017 - Acute myeloid leukemia (AML) is the most common form of acute leukemia among adults and accounts for the largest number of annual deaths due to leukemias in the United States. This portion of the NCCN Guidelines for AML focuses on management and p...

Acute myeloid leukemia, version 2.2013.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4161234
Journal of the National Comprehensive Cancer Network : JN... O'Donnell MR, Tallman MS et. al.

Sep 14th, 2013 - These NCCN Guidelines Insights summarize several key updates to the NCCN Guidelines for Acute Myeloid Leukemia and discuss the clinical evidence that support the recommendations. The updates described in this article focus on the acute promyelocyt...

Myelodysplastic syndromes: clinical practice guidelines in oncology.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4000017
Journal of the National Comprehensive Cancer Network : JN... Greenberg PL, Attar E et. al.

Jul 13th, 2013 - The myelodysplastic syndromes (MDS) represent a heterogeneous group of clonal hematopoietic disorders characterized by cytopenias, dysplasia in one or more myeloid lineages, and the potential for development of acute myeloid leukemia. These disord...

see more →

Drugs  28 results see all →

Clinicaltrials.gov  671 results

A Trial to Evaluate Two Schedules of MS275 in Combination With 5AC in Elderly Patients With Acute Myeloid Leukemia (AML)
https://clinicaltrials.gov/ct2/show/NCT01305499

May 8th, 2020 - To estimate the major response rate (complete and partial responses by the International Working Group (IWG) response criteria) in patients with AML who are >= 60 years old and unable to tolerate or decline cytotoxic chemotherapy or patients who h...

Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) Patients
https://clinicaltrials.gov/ct2/show/NCT02575963

May 7th, 2020 - The study is a multicenter, open label Phase I/II trial. Establish the MTD of fractionated doses of Lintuzumab-Ac225 in combination with low dose cytosine arabinoside (Low Dose Ara-C, LDAC) (Phase 1 portion) Determine the response rate (CR + CRp +...

Daunorubicin and Cytarabine With or Without Uproleselan in Treating Older Adult Patients With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
https://clinicaltrials.gov/ct2/show/NCT03701308

May 6th, 2020 - PRIMARY OBJECTIVES: I. Compare the event-free survival (EFS) of daunorubicin, cytarabine plus uproleselan versus daunorubicin and cytarabine in subjects >= age 60 with previously untreated acute myeloid leukemia. (Phase II) II. Compare the overall...

Pinometostat and Azacitidine in Treating Patients With Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia With 11q23 Rearrangement
https://clinicaltrials.gov/ct2/show/NCT03701295

May 5th, 2020 - PRIMARY OBJECTIVES: I. To determine if the combination of pinometostat, at a dose of 54 or 90 mg/m^2/day, and azacitidine, at a dose of 75 mg/m^2 daily for 7 days, is safe and tolerable in patients with MLL-rearranged acute myeloid leukemia, eithe...

Pinometostat With Standard Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and MLL Gene Rearrangement
https://clinicaltrials.gov/ct2/show/NCT03724084

May 5th, 2020 - PRIMARY OBJECTIVES: I. Determine a safe and tolerable schedule of pinometostat continuous intravenous infusion in combination with daunorubicin hydrochloride (daunorubicin) and cytarabine in patients with untreated, newly diagnosed acute myeloid l...

see more →

News  793 results

Ficlatuzumab Plus Chemo Shows Early Promise in Refractory AML
https://www.medscape.com/viewarticle/955064

Jul 21st, 2021 - NEW YORK (Reuters Health) - The combination of ficlatuzumab plus chemotherapy showed considerable early promise in relapsed/refractory acute myeloid leukemia (AML) in a small phase-1 study. "The high rate of complete remissions was surprising to u...

Hypomethylating Agents in Children With Relapsed/Refractory AML
https://www.medscape.com/viewarticle/953734

Jun 25th, 2021 - Hypomethylating agents are generally considered to be agents of choice for older adults with acute myeloid leukemia who cannot tolerate the rigors of more intensive therapies, but HMAs also can serve as a bridge to transplant for children and youn...

Reduced-Intensity Transplant Benefits Older Patients With AML
https://www.medscape.com/viewarticle/953436

Jun 21st, 2021 - Among older patients with acute myeloid leukemia (AML), survival is significantly better when they undergo reduced-intensity condition (RIC) before receiving an allogeneic hematopoietic cell transplant (HCT) at first remission. This improvement in...

Fast Five Quiz: Myelodysplastic Syndrome Presentation and Diagnosis
https://reference.medscape.com/viewarticle/950473

May 12th, 2021 - Myelodysplastic syndrome (MDS) is a group of related disorders that arise as the result of distorted hematopoietic stem cell function, inflammatory and innate immune deregulation, and multiple genomic events. These molecular alterations increase t...

Whole-Genome Sequencing Emerging for Routine Cancer Care
https://www.medscape.com/viewarticle/947261

Mar 11th, 2021 - Almost 20 years after the human genome was first mapped, whole-genome sequencing might finally be ready to enter routine cancer care. Researchers at Washington University in St. Louis, St. Louis, Missouri, are commercializing an automated sequenci...

see more →

Patient Education  5 results see all →